Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 2011. The report specifically details a share repurchase transaction executed on December 6, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback activity:
- Shares Purchased: 125,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,431.5 pence per share; lowest price paid was 1,405 pence per share.
- Treasury Holdings: Following the purchase, GSK holds 529,882,927 shares in Treasury (9.50% of total issued share capital).
- Voting Rights Impact: Including unsettled purchases, Treasury holdings represent 10.52% of current total voting rights.
- Shares in Issue: 5,047,374,518 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the acquisition of 125,000 shares for Treasury. This transaction increased the proportion of shares held in Treasury relative to the total issued share capital and voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase or subscribe for securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (529,882,927) against subsequent filings to track ongoing buyback activity.
- Confirm the denominator for voting rights calculations (5,047,374,518 shares in issue) for disclosure threshold assessments.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial results.